Search

everythinglearnresearchcommunity

for

Search:↓

The most common treatment for hair loss in the study was a 5% minoxidil solution, with women more likely to receive multiple medications. A significant number of patients also had hypothyroidism.

The combination therapy is safe and effective for treating Female Pattern Hair Loss in Asian women.

Hormonal therapies effectively treat acne and improve quality of life.

Hormonal therapies like cyproterone acetate and spironolactone may help some women with hair loss, but finasteride 1mg is not useful, and the effectiveness of other treatments is still unclear.

Hormonal therapy like cyproterone acetate and spironolactone may help female hair loss, but more research is needed, especially for pre-menopausal women.

Hormone treatment for transsexual individuals is effective but carries risks like thromboembolic events and mood changes, with most side effects being minor and reversible.

Minoxidil 2% and 5% are common treatments for female pattern hair loss, with other options including anti-androgens, oral contraceptives, and hair transplantation.

Female pattern hair loss is caused by multiple factors and while treatments like topical minoxidil, hormone therapy, and low-level light therapy can help, none can fully cure it.

10% minoxidil solution better promotes hair growth and reduces hair loss without significant side effects.

Female pattern hair loss has multiple causes and treatments, with new therapies showing promise.

Low-dose oral minoxidil effectively reduces hair loss in women with female pattern hair loss.

Different types of persistent hair loss after chemotherapy respond differently to treatments.

Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.

New and existing treatments for hair loss show promise, with some being more effective for men and others for women.

Personalized hair care strategies are needed for Black cancer patients to prevent hair loss during chemotherapy.

Gender-affirming therapy can cause skin issues like acne and hair loss in transgender adolescents, and more research is needed on its dermatological effects.

Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.

New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.

Current treatments for androgenetic alopecia are complex and promising, but more research is needed.

Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.

Hair loss in men and women can be treated with medications and therapies, showing improvement after 6 months.

Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.

Dermatologists recommend oral dutasteride for male hair loss, low-dose oral minoxidil for female hair loss, and a multidisciplinary approach for young patients, with caution during pregnancy.

Dermatologists are essential in helping transgender and gender diverse patients with skin and hair issues related to gender affirmation and hormone therapy.

Various treatments for common hair loss in men and women are effective, but should be tailored to individual needs and potential side effects.

A new psoriasis lotion called "Psorisbye" improved symptoms in a patient within one week.

Sex hormones affect hair growth and loss, and treatments for related hair diseases include various medications, hair transplantation, and light therapy.

Topical minoxidil is the primary treatment for female pattern hair loss in India.